Fulcrum Therapeutics’ (FULC) Market Perform Rating Reiterated at Leerink Partners

Leerink Partners reissued their market perform rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report report published on Thursday morning, MarketBeat reports. They currently have a $4.00 price objective on the stock.

Other analysts also recently issued research reports about the company. Stifel Nicolaus downgraded Fulcrum Therapeutics from a buy rating to a hold rating and dropped their target price for the stock from $22.00 to $3.00 in a research report on Thursday. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an overweight rating to a neutral rating in a research report on Thursday. Bank of America downgraded Fulcrum Therapeutics from a neutral rating to an underperform rating and dropped their target price for the stock from $10.00 to $2.00 in a research report on Thursday. Finally, HC Wainwright restated a buy rating and issued a $17.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of Hold and an average price target of $9.33.

Fulcrum Therapeutics Stock Down 7.6 %

FULC stock opened at $3.18 on Thursday. The firm has a market capitalization of $197.65 million, a PE ratio of -1.99 and a beta of 2.23. Fulcrum Therapeutics has a twelve month low of $2.87 and a twelve month high of $13.70. The stock has a 50-day simple moving average of $8.41 and a two-hundred day simple moving average of $8.27.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The company had revenue of $80.00 million during the quarter, compared to analyst estimates of $80.00 million. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. On average, equities research analysts anticipate that Fulcrum Therapeutics will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of FULC. Capstone Investment Advisors LLC bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $68,000. Affinity Asset Advisors LLC bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $844,000. Vestal Point Capital LP bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $6,919,000. ADAR1 Capital Management LLC bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $4,302,000. Finally, Opaleye Management Inc. bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $878,000. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.